Zhang Li Min
Zhang Li Min — Associate Chief Physician — Urology — Huashan Hospital Affiliated to Fudan University
Specialties
Focusing on minimally invasive surgery and comprehensive management of diseases such as prostate cancer, benign prostatic hyperplasia, urinary tract stones, and adrenal tumors; especially skilled in MR-US fusion-guided precise prostate biopsy, laparoscopic radical prostatectomy, prostate laser enucleation, laparoscopic adrenal tumor resection, and percutaneous nephrolithotomy, among others.
Education
Postdoctoral, Knight Cancer Research Center, University of Health and Science, USA PhD, Clinical Medicine (8-year program), Shanghai Medical College, Fudan University Bachelor's, Clinical Medicine (8-year program), Shanghai Medical College, Fudan University
Professional Experience
Medical Doctor, Associate Chief Physician of the Urology Department at Huashan Hospital. Postdoctoral Fellow at the Knight Cancer Research Center, Oregon Health & Science University, USA; Global Clinical Research Scholar at Harvard University, USA; Member and Secretary of the Minimally Invasive Surgery Group, Urology Specialty Committee, Shanghai Medical Association; Supervising Expert of the Expert Committee of the Shanghai Clinical Quality Control Center for Urology; Member of the American Society of Clinical Oncology (ASCO); Head of the MRI-Ultrasound Fusion Guided Prostate Precision Biopsy Project at Huashan Hospital Urology Department and the Geriatric Prostate Disease Specialized Outpatient Clinic. Main research focus on minimally invasive surgical treatment of prostate cancer, bladder cancer, kidney cancer, adrenal tumors, urolithiasis, and benign prostatic hyperplasia; annual outpatient cases over 2,000; clinical specialties include early precise diagnosis and integrated management of prostate cancer and minimally invasive treatment of benign prostatic hyperplasia. Surgical expertise includes laparoscopic radical prostatectomy, transurethral laser enucleation of the prostate, MR-US fusion guided prostate-targeted biopsy, laparoscopic adrenal tumor resection, percutaneous nephrolithotomy, and minimally invasive treatment of renal pelvis tumors under percutaneous nephroscopy. Principal investigator of one National Natural Science Foundation project, one clinical special project of the Shanghai Health Commission, and two hospital-level projects; published 12 papers in SCI journals. Participated in multiple phase II/III international multi-center clinical trials of new anti-urological tumor drugs.
Professional Roles
Member and secretary of the Minimally Invasive Surgery Group of the Urology Specialty Committee of the Shanghai Medical Association; supervising expert of the Expert Committee of the Shanghai Clinical Quality Control Center for Urology; member of the American Society of Clinical Oncology (ASCO)